Roche's China Buying Spree Continues With $1.53B Simcere Antibody Deal
- Roche will pay Simcere Zaiming $75M upfront for exclusive global rights to SIM0660, with up to $1.53B in total milestones plus tiered double-digit royalties.
- SIM0660 is a preclinical trispecific antibody combining a CD3 T-cell-engaging arm with two B-cell-targeting arms against CD79a and CD19.
- Dual B-cell antigen targeting is designed to broaden coverage across malignant and autoimmune B-cell populations, including patients who progressed on CD20- or CD19-directed therapies.
- A cytokine-limiting design aims to address the tolerability issues that have dogged earlier T-cell engagers.
- The deal is Roche's third Chinese in-licensing agreement in just over a week, extending a multi-year pattern of sourcing early-stage oncology and immunology assets from Chinese biotechs.
Dual-antigen targeting (CD79a + CD19) is the differentiator — most B-cell engagers still chase one antigen, so this asset is explicitly built for patients who've already progressed on CD19- or CD20-directed therapy, a relapse population CAR-T and existing bispecifics can't fully cover. $75M upfront against $1.53B in milestones is textbook preclinical pricing: Roche caps its downside, Simcere Zaiming carries the early clinical risk, and most of the payout hinges on the cytokine-limiting design actually solving the tolerability problem that's dogged prior T-cell engagers. Three China deals in barely a week isn't bargain-hunting — it's a systematic pipeline-refill strategy, treating Chinese biotech as a faster, cheaper source of differentiated immuno-oncology chemistry than internal discovery. As more Western majors chase this playbook, though, China-originated multispecifics could get crowded and bid up before any clear pivotal data emerges.
Roche inks $1.53B deal for Simcere's B-cell-targeting antibody ↗